Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

The final trades of the day with CNBC’s Melissa Lee and the Fast Money traders. The first migrant caravan of the year has set ...

The stock's fall snapped a two-day winning streak.

The pharmaceutical industry has bounced back in 2024. After barely growing by 0.5% in 2023, the sector has made a solid ...

Short BMY slightly under 59.95, target 53.71, stop loss @ 60.12 Check the time stamp on this data. Updated AI-Generated ...

Bristol Myers Squibb (BMY) closed the most recent trading day at $56.59, moving -0.35% from the previous trading session.

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was the target of some unusual options trading on Thursday. Investors purchased 296,826 call options on the stock. This represents an increase of 866% ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was the target of unusually large options trading activity on Thursday. Stock investors acquired 296,826 call options on the company. This is an ...

Bullish option flow detected in Bristol Myers ( BMY) Squibb with 203,938 calls trading, 22x expected, and implied vol increasing over 5 points to 22.90%. Jan-25 52.5 calls and Jan-25 50 calls are the ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report), with a price ...